Advocacy

ASAM serves its members in many ways. One of the most important ways is by helping to play an active role in shaping government policies that affect their livelihoods and the livelihoods of their patients.

ASAM advocates for policies that promote access to high-quality treatment and recovery support services for the 22 million Americans who suffer from a substance use disorder. The information here will help you stay up to date on emerging issues, enable you to take action and become an advocate for your patients and your practice, and learn about how ASAM is working with government, insurers and other national organizations to promote policies that advance addiction medicine.

CSOO

Opioid misuse and overdose are a public health crisis in the United States.  The American Society of Addiction Medicine (ASAM) and others have come together as the Coalition to Stop Opioid Overdose to advance meaningful legislative and regulatory policies this year in response to the opioid epidemic.

2016 NPF Training_472x176 

2016 NPF Training

Audio, text, slides, photos and selected 5-minute videos segments from the 2016 NPF/ ASAM Training held in April 2016 preceding the 47th ASAM Annual Conference in Baltimore, MD.

Events_472x176

Advocacy Events

Sign up to participate in advocacy events and learn about the latest happenings on Capitol Hill.

Advocacy Events_472x176

Advocacy Issues

Find the latest information on issues of importance to the field of addiction medicine.

NPF training_472x176

Advocacy News

News and information about ASAM Advocacy.

Find a Policy Statement_472x176

Find a Policy Statement

Learn about ASAM's position on current policy issues.

Advocacy Toolkits_472x176

Advocacy Toolkits

Access resources that will equip you to advocate effectively for policies that promote addiction treatment and prevention.

Staff

Kelly Corredor
Director, Advocacy and Government Relations
kcorredor@ASAM.org | .301.547.4111

 

Susan Awad
Policy Advisor
sawad@ASAM.org | .301.547.4103

 

Corey Barton
Manager, Private Sector Relations
cbarton@ASAM.org | 301.547.4106

 

Brad Bachman
Manager, State Government Relations
bbachman@ASAM.org | 301.547.4107

 

Connor Galvin
Coordinator, Advocacy, Policy and Payer Relations
cgalvin@ASAM.org | 301.547.4135

Committee Chairs

Corey Waller, MD, MS, FACEP
Flora Sadri, DO, MPF, FAAFP

Chair and Vice Chair, Legislative Advocacy Committee

 

Jeffrey Selzer, MD, DFASAM
Randolph Holmes, MD, FASAM

Chair and Vice Chair, Public Policy Committee

 

Shawn Ryan, MD, MBA, FASAM
Frank James, MD, JD

Chair and Vice Chair, Payer Relations Committee

ASAM Welcomes New CMS Direction on Section 1115 Waivers

by ASAM Staff | Nov 06, 2017

Last week, the Centers for Medicare and Medicaid Services (CMS) issued new guidance to State Medicaid Directors on section 1115(a) demonstrations designed to improve quality of and access to treatment for addiction. This new direction supersedes previous guidance and is intended to streamline the review of section 1115(a) demonstrations. It also encourages states to engage in demonstrations that provide the full continuum of care for people with addiction, including in residential and inpatient treatment centers where Medicaid reimbursement is limited or nonexistent.

The American Society of Addiction Medicine (ASAM) commends CMS for issuing this new guidance which expands access to care and requires states to align their section 1115(a) demonstrations with certain goals and milestones. Milestones include using evidence-based guides, such as The ASAM Criteria, for patient placement; maintaining adequate provider capacity at each level of care; utilizing nationally recognized program standards, such as those in The ASAM Criteria, to set residential treatment provider qualifications; and improving care coordination. This new policy is a step in the right direction and aligns with some of the previous recommendations made by ASAM and the President’s Commission on Combating Drug Addiction and the Opioid Crisis.  

ASAM, however, also urges CMS to ensure that  treatment provider assessments for all addiction treatment services, levels of care, and length-of-stay recommendations, as well as methods of residential treatment provider qualification, are performed by an independent third party that has the necessary competencies to use The ASAM Criteria (or such other evidence-based patient placement assessment tools and nationally-recognized program standards, as applicable). More than 30 states already use The ASAM Criteria, and with this combination of steps, our country can further improve the quality of care so that only evidence-based treatment is covered by Medicaid. Specifically, ASAM has several ways to assist states in implementing section 1115(a) waiver requirements, including a suite of ASAM Criteria assessment tools called CONTINUUM, The ASAM Criteria Decision Engine™. Dr. Kelly Clark, president of ASAM, had this to say about the new guidance from CMS:

“ASAM welcomes this move by CMS which advances evidence-based care and accountability in treatment. It’s important that people get the right care, in the right place, and at the right time by using evidence-based criteria such as The ASAM Criteria. This new policy goes a long way toward ensuring that patients can feel confident that the kind of treatment recommended and being received is consistent with good medical care standards. We look forward to working with Congress, the administration, and our partners at the state and local levels to ensure that funding is utilized in the most efficient and effective way to combat this epidemic.”

###

Advocacy Articles

ASAM Welcomes New CMS Direction on Section 1115 Waivers

by ASAM Staff | Nov 06, 2017

Last week, the Centers for Medicare and Medicaid Services (CMS) issued new guidance to State Medicaid Directors on section 1115(a) demonstrations designed to improve quality of and access to treatment for addiction. This new direction supersedes previous guidance and is intended to streamline the review of section 1115(a) demonstrations. It also encourages states to engage in demonstrations that provide the full continuum of care for people with addiction, including in residential and inpatient treatment centers where Medicaid reimbursement is limited or nonexistent.

The American Society of Addiction Medicine (ASAM) commends CMS for issuing this new guidance which expands access to care and requires states to align their section 1115(a) demonstrations with certain goals and milestones. Milestones include using evidence-based guides, such as The ASAM Criteria, for patient placement; maintaining adequate provider capacity at each level of care; utilizing nationally recognized program standards, such as those in The ASAM Criteria, to set residential treatment provider qualifications; and improving care coordination. This new policy is a step in the right direction and aligns with some of the previous recommendations made by ASAM and the President’s Commission on Combating Drug Addiction and the Opioid Crisis.  

ASAM, however, also urges CMS to ensure that  treatment provider assessments for all addiction treatment services, levels of care, and length-of-stay recommendations, as well as methods of residential treatment provider qualification, are performed by an independent third party that has the necessary competencies to use The ASAM Criteria (or such other evidence-based patient placement assessment tools and nationally-recognized program standards, as applicable). More than 30 states already use The ASAM Criteria, and with this combination of steps, our country can further improve the quality of care so that only evidence-based treatment is covered by Medicaid. Specifically, ASAM has several ways to assist states in implementing section 1115(a) waiver requirements, including a suite of ASAM Criteria assessment tools called CONTINUUM, The ASAM Criteria Decision Engine™. Dr. Kelly Clark, president of ASAM, had this to say about the new guidance from CMS:

“ASAM welcomes this move by CMS which advances evidence-based care and accountability in treatment. It’s important that people get the right care, in the right place, and at the right time by using evidence-based criteria such as The ASAM Criteria. This new policy goes a long way toward ensuring that patients can feel confident that the kind of treatment recommended and being received is consistent with good medical care standards. We look forward to working with Congress, the administration, and our partners at the state and local levels to ensure that funding is utilized in the most efficient and effective way to combat this epidemic.”

###